Related Experiment Video
Updated: Jun 5, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody
Renae Walsh1, Stewart Nuttall, Peter Revill
1Victorian Infectious Diseases Reference Laboratories, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia. renae.walsh@mh.org.au
Abstract:
The Hepatitis B virus precore protein is processed in the endoplasmic reticulum (ER) into secreted hepatitis B e antigen (HBeAg), which acts as an immune tolerogen to establish chronic infection. Downregulation of secreted HBeAg should improve clinical outcome, as patients who effectively respond to current treatments (IFN-α) have significantly lower serum HBeAg levels. Here, we describe a novel reagent, a single variable domain (V(NAR)) of the shark immunoglobulin new antigen receptor (IgNAR) antibodies. V(NAR)s possess advantages in stability, size (~14 kDa) and cryptic epitope recognition compared to conventional antibodies. The V(NAR) domain displayed biologically useful affinity for recombinant and native HBeAg, and recognised a unique conformational epitope. To assess therapeutic potential in targeting intracellular precore protein to reduce secreted HBeAg, the V(NAR) was engineered for ER-targeted in vitro delivery to function as an intracellular antibody (intrabody). In vitro data from HBV/precore hepatocyte cell lines demonstrated effective intrabody regulation of precore/HBeAg.
More Related Videos
Related Concept Videos
Inhibitors Of Virion Release
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

